Is a MUSE Cell or an iPS Cell Safer and More Practical?
Patients often hear about iPS cells in the news and MUSE cells from clinics, and ask which is better. The honest answer is that they are different tools with different risks. Comparing MUSE cells vs iPS cells starts with where each comes from.
How MUSE Cells and iPS Cells Differ in Origin
iPS cells: Takahashi and Yamanaka showed in 2006 that adding four factors (Oct3/4, Sox2, c-Myc and Klf4) could reprogramme mouse fibroblasts into pluripotent cells. The cells are made in a laboratory.
MUSE cells: Kuroda and colleagues described them in 2010 as a small, stress-tolerant population within adult mesenchymal cells, identified by the marker SSEA-3. They already exist in the body and are collected, not created.
Wakao and colleagues later reported that in human fibroblasts, iPS cells arose mainly from the MUSE cell fraction.
MUSE Cells vs iPS Cells Side by Side
| Consideration | iPS cells | MUSE cells |
|---|---|---|
| Origin | Created by reprogramming adult cells | Naturally occurring, collected from tissue |
| Genetic change | Reprogramming factors introduced | No genetic modification |
| Teratoma concern | Undifferentiated cells can form teratomas | No teratomas in the original mouse testis tests |
| Preparation before use | Usually differentiated into a target cell first | Given intravenously in published early studies |
| Donor matching | Depends on the programme | Early studies used donor cells without HLA matching or immunosuppressants |
| Clinical status | Investigational for most uses | Investigational, early-phase studies |
How MUSE Cells and iPS Cells Differ in Safety
For iPS-based products, the main questions are whether any undifferentiated cells remain and whether reprogramming changed the genome. For MUSE products, the questions focus on donor screening, immune tolerance over time and product consistency.
A lower tumour concern in animal tests does not prove long-term human safety. Our MUSE safety guide covers this in more detail.
MUSE Cell Therapy Approach Compared With iPS Cells
- How it works: MUSE cells are proposed to home to damaged tissue after intravenous infusion. This is under investigation.
- Who may be suitable: only people matching a specific study or regulated pathway for their condition.
- What a session involves: published studies used intravenous infusion with medical monitoring and follow-up.
- Limits: early-phase evidence in a few conditions only. It is not a substitute for proven care.
See condition studies on stroke, heart attack, epidermolysis bullosa and liver cirrhosis. For broader background, read our types of stem cells guide, our article on preparing MSCs before treatment and the early question of MUSE cells and ear ringing.
How to Tell a MUSE Product From an iPS Product
- Is the cell naturally collected or reprogrammed?
- Which tissue and donor does it come from?
- What identity and sterility tests are on the release document? See how MUSE cells are quality tested.
- Which published studies match my condition?
Bottom line: MUSE and iPS cells differ in origin and risk profile. Neither is a proven routine treatment yet.
Medical References
- Takahashi K and Yamanaka S, 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
- Kuroda Y and colleagues, 2010. Unique multipotent cells in adult human mesenchymal cell populations
- Wakao S and colleagues, 2011. Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts
- Minatoguchi S and colleagues, 2024. Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment
Talk to a Doctor Before You Decide
Bring the name of any cell product you have been offered. Our team can explain where it comes from and what evidence applies to it.
Schedule a Consultation





